Abstract

Background and AimsCholestatic liver injury (CLI), which is associated with inflammatory reactions and oxidative stress, is a serious risk factor for postoperative complications. Complement system is involved in a wide range of liver disorders, including cholestasis. The present study assessed the role of complement in CLI and the therapeutic effect of the site-targeted complement inhibitor CR2-Crry in CLI.MethodsWild-type and complement gene deficient mice underwent common bile duct ligation (BDL) to induce CLI or a sham operation, followed by treatment with CR2-Crry or GdCl3. The roles of complement in CLI and the potential therapeutic effects of CR2-Crry were investigated by biochemical analysis, flow cytometry, immunohistochemistry, ELISA, and quantitative RT-PCR.ResultsC3 deficiency and CR2-Crry significantly reduced liver injuries in mice with CLI, and also markedly decreasing the numbers of neutrophils and macrophages in the liver. C3 deficiency and CR2-Crry also significantly reduced neutrophil expression of Mac-1 and liver expression of VCAM-1. More importantly, C3 deficiency and CR2-Crry significantly inhibited M1 macrophage polarization in these mice. Intravenous injection of GdCl3 inhibited macrophage infiltration and activation in the liver. However, the liver injury increased significantly. BDL significantly increased the level of lipopolysaccharide (LPS) in portal blood, but not in peripheral blood. GdCl3 significantly increased LPS in peripheral blood, suggesting that macrophages clear portal blood LPS. Oral administration of ampicillin to in GdCl3 treated mice reduced LPS levels in portal blood and alleviated liver damage. In contrast, intraperitoneal injection LPS increased portal blood LPS and reversed the protective effect of ampicillin. Interestingly, C3 deficiency did not affect the clearance of LPS.ConclusionsComplement is involved in CLI, perhaps mediating the infiltration and activation of neutrophils and macrophage M1 polarization in the liver. C3 deficiency and CR2-Crry significantly alleviated CLI. Inhibition of complement could preserve the protective function of macrophages in clearing LPS, suggesting that complement inhibition could be useful in treating CLI.

Highlights

  • Cholestatic liver injury (CLI) can be caused by a variety of hepatobiliary and pancreatic diseases, such as cholangiocarcinoma, common bile duct stones, and pancreatic neoplasms

  • Because CLI depends on inflammatory reaction, and the complement system is involved in its pathogenesis [3, 12], we hypothesized that blocking complement activation could alleviate CLI

  • C3d and membrane attack complex (MAC) were not deposited in the liver of sham-operated mice, whereas large amounts of C3d and MAC were deposited observed in the livers of WT-bile duct ligation (BDL) mice

Read more

Summary

Introduction

Cholestatic liver injury (CLI) can be caused by a variety of hepatobiliary and pancreatic diseases, such as cholangiocarcinoma, common bile duct stones, and pancreatic neoplasms. The mechanism underlying CLI has been shown to depend on sterile inflammatory reactions and oxidative stress [3]. The serum concentrations of activated complement components have been reported to correlate positively with the degree of CLI [13, 14]. These observations provide evidence that complement activation correlates with both cholestasis and inflammatory liver injury in CLI, but the underlying mechanisms remain unclear. Cholestatic liver injury (CLI), which is associated with inflammatory reactions and oxidative stress, is a serious risk factor for postoperative complications. The present study assessed the role of complement in CLI and the therapeutic effect of the site-targeted complement inhibitor CR2-Crry in CLI

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call